COPD ExacerbationNCT02619903
The Oral Microbiota as Reservoir for Systemic Opportunistic Pathogens
A study testing Dental cleaning in people with COPD Exacerbation and Pulmonary Disease, Chronic Obstructive, run by Malmö University at 2 sites in Sweden.
Trial summary
Small pilot studies with approximately 20 people per group support that eradication of the oral flora causes fewer exacerbations in chronic obstructive pulmonary disease (COPD) patients. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- COPD Exacerbation, Pulmonary Disease, Chronic Obstructive, Dental Plaque
- What is being tested?
- Dental cleaning
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 101 participants
- Where
- 2 sitesSweden
- Study dates
- Feb 2016to 31 Dec 2020
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- COPD arm - COPD Gold standard 1-4.
Who cannot join
- Physically unable to make it to the dental clinic.
Trial locations and contacts
2 sites in 1 country.
About this study
Small pilot studies with approximately 20 people per group support that eradication of the oral flora causes fewer exacerbations in chronic obstructive pulmonary disease (COPD) patients. The biological underpinning put forward is that eradicating the oral microbiome will eliminate a source of re-infection as the concentration of antibiotics prescribed to treat COPD exacerbations are not able to inhibit the bacteria in the oral biofilms that require 250 times higher concentration.
The specific aim is to investigate if adding advanced dental cleaning to COPD treatment can (i) lower the number of exacerbations and (ii) improve the COPD symptoms the coming 12 months. In an effort to explain the underpinning mechanism we will collect oral dental biofilm samples at baseline and follow up in the treatment and control group to investigate changes in the composition of the biofilm.
Read more
The subjects are selected by experienced COPD nurses. Exclusion criteria are having metastatic cancer or dementia. The COPD clinic informs the dental personal about COPD parameters, including spirometry data. At the dental clinic the patient answers a questionnaire, including a COPD assessment test (CAT) which has been validated extensively. The patients undergo a dental examination and are then randomized to test or control group. The test group go through supra- and subgingival scaling and scraping of the tongue as well as chlorhexidine rinse. The control group attends all visits.
All subjects go through the intervention after 6 months and are followed up after 12 and 24 months using questionnaire, dental plaque sampling and spirometry. The COPD nurses reviewing their medical records assess number of exacerbations.
A confirmation of the study hypothesis will be important in lowering the number of exacerbations in COPD patients, causing less suffering, less costs and less usage of antibiotics. If dental treatment is beneficial for exacerbation frequency it could be argued that dental treatment should be subsidized in this patient category.
Read the detailed description
Introduction The dental biofilm offers a protected environment for bacteria during systemic antibiotic treatment and may consequently be a source of reinfection. The concentration of antibiotic needed for inhibiting the growth of bacteria within a dental biofilm has been estimated to be 250 times greater than for planktonically growing bacteria (1). Chronic obstructive pulmonary disease (COPD) exacerbations cause pain and discomfort for the patient, healthcare resources and an increased usage of antibiotics. Smaller studies indicate that the act of advanced dental cleaning may lower the risk of reinfected COPD, but this needs to be validated in a larger randomized study to promote clinical implications.
COPD is a growing health problem worldwide. In 2020, COPD is projected to rank fifth in terms of burden of disease and third in terms of mortality (2). Assessment of COPD is based on the patient´s level of symptoms, exacerbation history and severity of spirometric abnormality. In a randomly selected Swedish cohort, the prevalence of COPD was 16.2%, and 34% of the COPD patients had never smoked (3). Unfortunately, none of the existing medications for COPD has been shown conclusively to modify the long-term decline in lung-function, but COPD patients are usually prescribed β2-adrenerg receptor agonists and anticholinergics (2). For acute exacerbations, the patients have oral steroids and antibiotics, typically doxycycline and amoxicillin. Importantly, two smaller (n=20 per group) pilot studies (4,5) have reported a lower frequency of exacerbations in COPD patients that have received advanced dental cleaning, suggesting that the oral microbiome might constitute a reservoir that infects the lungs in COPD. There is a need of studies based on larger cohorts in order to claim that dental treatment should be added to the treatment regime of COPD, to decrease the frequencies of exacerbations and thereby minimize physical suffering as well as related costs.
Hypothesis The hypothesis of this project is that adding advanced dental cleaning to established COPD treatment regime delays and lowers the frequency of exacerbations by eliminating a source of reinfections.
Aim The overall aim of this project is to investigate if the treatment of COPD can be optimized by adding advanced dental cleaning to the established treatment regime and thereby eliminate a source of reinfections.
The specific aim is to investigate if adding advanced dental cleaning to COPD treatment can (i) lower the number of exacerbations and (ii) improve the COPD symptoms the coming 6 and 12 months. In an effort to explain the underpinning mechanism we will collect oral dental biofilm samples at baseline and follow up in the treatment and control group to investigate changes in the composition of the biofilm.
COPD project At the lung clinic The COPD project will be conducted at Region Skane lung clinic and in collaboration with the COPD clinics in Skne In Örebro the subjects will be recruited from the lung clinic in collaboration with Dr. Josefin Sundh and the dental cleaning will be performed at the dental specialist clinic, folktandvarden Örebro. A COPD patient will be informed about the current study by a nurse. The patient will be asked to sign a consent and handed the written information including the number to the dental clinic.
At the dental clinic The dental clinic receives a phone call from the person who just signed a consent; alternatively, a nurse at the dental clinic calls the patient. At the dental clinic the patient is randomized to, either the advanced dental cleaning group, or a control group by the dentist or dental hygienist at the dental clinic. When the patient comes to the dental visit, both groups undergo a periodontal examination and microbiological sampling.
Questionnaire - Upon arriving at the dental clinic, the participant is asked to fill out a questionnaire that includes medical history and CAT-questionnaire.
The microbiological sampling is done by collecting the GenoTek tube by sampling the dental plaque samples.
Periodontal examination is performed on 6 sites per tooth including the third molar. Periodontal pockets ≥ 4mm are registered as well as bleeding upon probing, plaque index and attachment loss.
Intervention - The oral biofilm will be disrupted and removed on the sub- as well as supragingival surfaces of the teeth. Supragingival surfaces will be cleaned using the prophylactic paste RDA 250 supplemented with curettes and ultrasonic debridement. Subgingival surfaces will be cleaned using curettes and ultrasonic debridement when indicated based on the periodontal examination. The tongue will be cleaned using a tongue scraper. Finally, the patient will be asked to rinse 10 ml of 2 mg/ml chlorhexidine mouth rinse for one minute.
Follow-up - After 6 months, 12 months and 24 months the participants revisits the dental clinic. They fill out a new CAT form and a questionnaire asking how many exacerbations that needed medical attention since they joined the study (this is double checked in their medical records), if they have taken antibiotics for any other reason or changed their medications in any way. They are also asked about any dental treatments.
Microbiological analysis The subsequent microbiological analysis will be executed using deep sequencing, as well as qPCR.
Time schedule 2016-2017 - Participants are recruited, randomized and the treatment group is treated. 2017-2020 - Participants are followed up.
2020 - Data analysis and publication.
Network Daniel Jönsson - PhD in 2007 and a postdoc on the systemic effects of periodontal disease in 2009 and 2010 at Columbia University, New York, NY, USA. Became a specialist in periodontics in 2014 and currently positioned at Malmö University and Region Skane, Lund. Dr. Jönsson will start a part time position in Örebro in 2016.
Bodil Ohlsson - Professor and specialist in Internal Medicine and Gastroenterology at Lund University and Region Skane University hospital.
Hanan Tanash - PhD and specialist in Internal Medicine. Field of interest - COPD.
Josefin Sundh - Associate Professor at Örebro University hospital. Field of interest - COPD.
Frida Fak - Associate Professor at Lund University. Field of interest - microbiology.
Folktandvarden Skane - two dental hygienists have been recruited for the project.
Folktandvarden Örebro - a post-graduate student is being recruited for the dental cleaning as well as managing the logistics of the project. Daniel Jönsson will be the supervisor of the student.
Power analysis In a power analysis based on the standard deviations from the pilot study of Kucukoskun et al. [3] indicated 80% power to detect a difference of p<0.05 of 1.5 exacerbations per year in a sample of 49 subjects in each group.
Significance As antibiotics is part of the COPD treatment regime this study may restrict the usage of antibiotics, minimizing antibiotic resistance. COPD exacerbations disable the person to go to work which causes financial consequences, but also healthcare expenses. Most importantly, the study will plausibly improve life quality and extend the life span of patients suffering from COPD. We already have preliminary data that subjects in the treatment group have an OR 3.9 for being stable or having less COPD-symptoms in this progressive disease.
- Being tested
- Dental cleaning
- Medical subject headings
- Pulmonary Disease, Chronic Obstructive, Dental Plaque
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Dental cleaningProcedure or surgery
Dental scaling and cleaning to remove dental plaque as well as removing the tongue biofilm.
| Study group | Role | What they receive |
|---|---|---|
| COPD Control | No intervention | Subjects with COPD recieve no treatment. When exiting the trial after 12 months, they do however receive the intervention. |
| COPD Test | Active comparator | Subjects with COPD that do get the additional dental cleaning, as well as dental examination. Receives: Procedure: Dental cleaning |
What is being measured
The primary outcome is the main question the study is designed to answer.
COPD exacerbations in 12 months
We will ask the patients how many exacerbations they had and go through medical records.
Measured: 12 months
Secondary outcomes (1)
COPD symptoms
COPD symptoms based on CAT-score (COPD Assessment Test)
Measured: 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Dec 2015 (estimated)
- Study startFeb 2016
- Primary completion31 Dec 2020
- Study completion31 Dec 2020
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for COPD ExacerbationStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Test versus control for dental treatment in attenuating exacerbations in COPD.
- Masking
- Double blind
- Who is masked
- Investigator, Outcomes assessor
- Enrolment
- 101 participants (actual)
Sponsor and investigators
- Lead sponsor
- Malmö University
- Sponsor type
- University, hospital or other
- Collaborators
- Lund University
- Responsible party
- Principal investigator, Daniel Joensson, Malmö University
- Investigators
- Daniel Jönsson, DDS, PhD, Principal investigator, Lund University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02619903
- Sponsor's protocol ID
- 2015-279
- Status last verified
- Jun 2021
- First submitted
- 29 Nov 2015
- Last updated
- 25 Jun 2021
- Results posted
- No
- Data monitoring committee
- Yes
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 25 Jun 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Oral Microbiota as Reservoir for Systemic Opportunistic Pathogens
- ClinicalTrials.gov ID
- NCT02619903
- Acronym / sponsor ID
- 2015-279
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 101 participants (actual)
- Lead sponsor
- Malmö UniversityUniversity, hospital or other
- Collaborators
- Lund University
- Study start
- Feb 2016
- Primary completion
- 31 Dec 2020 (actual)
- Study completion
- 31 Dec 2020 (actual)
- First posted
- 2 Dec 2015 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Small pilot studies with approximately 20 people per group support that eradication of the oral flora causes fewer exacerbations in chronic obstructive pulmonary disease (COPD) patients. The biological underpinning put forward is that eradicating the oral microbiome will eliminate a source of re-infection as the concentration of antibiotics prescribed to treat COPD exacerbations are not able to inhibit the bacteria in the oral biofilms that require 250 times higher concentration.
The specific aim is to investigate if adding advanced dental cleaning to COPD treatment can (i) lower the number of exacerbations and (ii) improve the COPD symptoms the coming 12 months. In an effort to explain the underpinning mechanism we will collect oral dental biofilm samples at baseline and follow up in the treatment and control group to investigate changes in the composition of the biofilm.
The subjects are selected by experienced COPD nurses. Exclusion criteria are having metastatic cancer or dementia. The COPD clinic informs the dental personal about COPD parameters, including spirometry data. At the dental clinic the patient answers a questionnaire, including a COPD assessment test (CAT) which has been validated extensively. The patients undergo a dental examination and are then randomized to test or control group. The test group go through supra- and subgingival scaling and scraping of the tongue as well as chlorhexidine rinse. The control group attends all visits.
All subjects go through the intervention after 6 months and are followed up after 12 and 24 months using questionnaire, dental plaque sampling and spirometry. The COPD nurses reviewing their medical records assess number of exacerbations.
A confirmation of the study hypothesis will be important in lowering the number of exacerbations in COPD patients, causing less suffering, less costs and less usage of antibiotics. If dental treatment is beneficial for exacerbation frequency it could be argued that dental treatment should be subsidized in this patient category.
Detailed description
Introduction The dental biofilm offers a protected environment for bacteria during systemic antibiotic treatment and may consequently be a source of reinfection. The concentration of antibiotic needed for inhibiting the growth of bacteria within a dental biofilm has been estimated to be 250 times greater than for planktonically growing bacteria (1). Chronic obstructive pulmonary disease (COPD) exacerbations cause pain and discomfort for the patient, healthcare resources and an increased usage of antibiotics. Smaller studies indicate that the act of advanced dental cleaning may lower the risk of reinfected COPD, but this needs to be validated in a larger randomized study to promote clinical implications.
COPD is a growing health problem worldwide. In 2020, COPD is projected to rank fifth in terms of burden of disease and third in terms of mortality (2). Assessment of COPD is based on the patient´s level of symptoms, exacerbation history and severity of spirometric abnormality. In a randomly selected Swedish cohort, the prevalence of COPD was 16.2%, and 34% of the COPD patients had never smoked (3). Unfortunately, none of the existing medications for COPD has been shown conclusively to modify the long-term decline in lung-function, but COPD patients are usually prescribed β2-adrenerg receptor agonists and anticholinergics (2). For acute exacerbations, the patients have oral steroids and antibiotics, typically doxycycline and amoxicillin. Importantly, two smaller (n=20 per group) pilot studies (4,5) have reported a lower frequency of exacerbations in COPD patients that have received advanced dental cleaning, suggesting that the oral microbiome might constitute a reservoir that infects the lungs in COPD. There is a need of studies based on larger cohorts in order to claim that dental treatment should be added to the treatment regime of COPD, to decrease the frequencies of exacerbations and thereby minimize physical suffering as well as related costs.
Hypothesis The hypothesis of this project is that adding advanced dental cleaning to established COPD treatment regime delays and lowers the frequency of exacerbations by eliminating a source of reinfections.
Aim The overall aim of this project is to investigate if the treatment of COPD can be optimized by adding advanced dental cleaning to the established treatment regime and thereby eliminate a source of reinfections.
The specific aim is to investigate if adding advanced dental cleaning to COPD treatment can (i) lower the number of exacerbations and (ii) improve the COPD symptoms the coming 6 and 12 months. In an effort to explain the underpinning mechanism we will collect oral dental biofilm samples at baseline and follow up in the treatment and control group to investigate changes in the composition of the biofilm.
COPD project At the lung clinic The COPD project will be conducted at Region Skane lung clinic and in collaboration with the COPD clinics in Skne In Örebro the subjects will be recruited from the lung clinic in collaboration with Dr. Josefin Sundh and the dental cleaning will be performed at the dental specialist clinic, folktandvarden Örebro. A COPD patient will be informed about the current study by a nurse. The patient will be asked to sign a consent and handed the written information including the number to the dental clinic.
At the dental clinic The dental clinic receives a phone call from the person who just signed a consent; alternatively, a nurse at the dental clinic calls the patient. At the dental clinic the patient is randomized to, either the advanced dental cleaning group, or a control group by the dentist or dental hygienist at the dental clinic. When the patient comes to the dental visit, both groups undergo a periodontal examination and microbiological sampling.
Questionnaire - Upon arriving at the dental clinic, the participant is asked to fill out a questionnaire that includes medical history and CAT-questionnaire.
The microbiological sampling is done by collecting the GenoTek tube by sampling the dental plaque samples.
Periodontal examination is performed on 6 sites per tooth including the third molar. Periodontal pockets ≥ 4mm are registered as well as bleeding upon probing, plaque index and attachment loss.
Intervention - The oral biofilm will be disrupted and removed on the sub- as well as supragingival surfaces of the teeth. Supragingival surfaces will be cleaned using the prophylactic paste RDA 250 supplemented with curettes and ultrasonic debridement. Subgingival surfaces will be cleaned using curettes and ultrasonic debridement when indicated based on the periodontal examination. The tongue will be cleaned using a tongue scraper. Finally, the patient will be asked to rinse 10 ml of 2 mg/ml chlorhexidine mouth rinse for one minute.
Follow-up - After 6 months, 12 months and 24 months the participants revisits the dental clinic. They fill out a new CAT form and a questionnaire asking how many exacerbations that needed medical attention since they joined the study (this is double checked in their medical records), if they have taken antibiotics for any other reason or changed their medications in any way. They are also asked about any dental treatments.
Microbiological analysis The subsequent microbiological analysis will be executed using deep sequencing, as well as qPCR.
Time schedule 2016-2017 - Participants are recruited, randomized and the treatment group is treated. 2017-2020 - Participants are followed up.
2020 - Data analysis and publication.
Network Daniel Jönsson - PhD in 2007 and a postdoc on the systemic effects of periodontal disease in 2009 and 2010 at Columbia University, New York, NY, USA. Became a specialist in periodontics in 2014 and currently positioned at Malmö University and Region Skane, Lund. Dr. Jönsson will start a part time position in Örebro in 2016.
Bodil Ohlsson - Professor and specialist in Internal Medicine and Gastroenterology at Lund University and Region Skane University hospital.
Hanan Tanash - PhD and specialist in Internal Medicine. Field of interest - COPD.
Josefin Sundh - Associate Professor at Örebro University hospital. Field of interest - COPD.
Frida Fak - Associate Professor at Lund University. Field of interest - microbiology.
Folktandvarden Skane - two dental hygienists have been recruited for the project.
Folktandvarden Örebro - a post-graduate student is being recruited for the dental cleaning as well as managing the logistics of the project. Daniel Jönsson will be the supervisor of the student.
Power analysis In a power analysis based on the standard deviations from the pilot study of Kucukoskun et al. [3] indicated 80% power to detect a difference of p<0.05 of 1.5 exacerbations per year in a sample of 49 subjects in each group.
Significance As antibiotics is part of the COPD treatment regime this study may restrict the usage of antibiotics, minimizing antibiotic resistance. COPD exacerbations disable the person to go to work which causes financial consequences, but also healthcare expenses. Most importantly, the study will plausibly improve life quality and extend the life span of patients suffering from COPD. We already have preliminary data that subjects in the treatment group have an OR 3.9 for being stable or having less COPD-symptoms in this progressive disease.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (investigator, outcomes assessor)
- Number of arms
- 2
- Model description
- Test versus control for dental treatment in attenuating exacerbations in COPD.
| Arm | Type | Receives |
|---|---|---|
| COPD Control | No intervention | –Subjects with COPD recieve no treatment. When exiting the trial after 12 months, they do however receive the intervention. |
| COPD Test | Active comparator | Procedure: Dental cleaningSubjects with COPD that do get the additional dental cleaning, as well as dental examination. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- COPD arm - COPD Gold standard 1-4.
Key exclusion criteria (1 listed)
- Physically unable to make it to the dental clinic.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Dental cleaningDental scaling and cleaning to remove dental plaque as well as removing the tongue biofilm. | Procedure or surgery | COPD Test |
Primary outcome
COPD exacerbations in 12 months
Time frame: 12 months
We will ask the patients how many exacerbations they had and go through medical records.
1 secondary outcome
COPD symptoms
Time frame: 12 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 Jun 2021.
- Individual participant dataSharing planned: No
Related trials for COPD Exacerbation
Active, not recruiting
Influence of FreeO2 on Percentage of Time Within Oxygen Saturation Target Using Noninvasive Ventilation (NIV) and Continuous Positive Airway Pressure (CPAP) for Patients Admitted for AECOPD or Bariatric Surgery
COPD Exacerbation, Oxygen Toxicity
Active, not recruiting
FreeDom: Innovative Strategy for the Management of COPD Exacerbations
Oxygen Deficiency, COPD Exacerbation
RecruitingPhase 2
Rademikibart IV for Acute Asthma and COPD Exacerbation
Asthma Acute, COPD Exacerbation Acute
Not yet recruitingPhase 1
Investigating Senolytic Properties in Pulmonary Rehabilitation and Metformin in COPD Exacerbations
Chronic Obstructive Pulmonary Disease (COPD)
RecruitingObservational study
Swiss Chronic Obstructive Pulmonary Disease (COPD) Management Cohort
Chronic Obstructive Pulmonary Disease, COPD Exacerbation
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Daniel Jönsson, DDS, PhD principal investigator
Lund University
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Dental cleaning in people with COPD Exacerbation and Pulmonary Disease, Chronic Obstructive, run by Malmö University at 2 sites in Sweden.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 25 Jun 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Sweden. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
COPD exacerbations in 12 months (time frame: 12 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Jun 2021.